Optimal stent placement strategy for malignant hilar biliary obstruction: a large multicenter parallel study

• Published in: Gastrointestinal endoscopy Vol. 91; no. 5; pp. 1117 - 1128.e9
• Main Authors: Xia, Ming-Xing, Cai, Xiao-Bo, Pan, Yang-Lin, Wu, Jun, Gao, Dao-Jian, Ye, Xin, Wang, Tian-Tian, Hu, Bing
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2020
• Subjects: Bile Duct Neoplasms - complications; Cholestasis - etiology; Cholestasis - surgery; Endoscopy; Humans; Palliative Care; Retrospective Studies; Stents; Treatment Outcome; PTCD; OR; BPS; OS; CI; BMS; UPS; HR; UMS; PSM; MHBO; SEMS
• ISSN: 0016-5107; 1097-6779
• DOI: 10.1016/j.gie.2019.12.023

The endoscopic management of malignant hilar biliary obstruction (MHBO) remains extremely challenging without universal consensus. For the first time, we compared 4 major modalities aiming to determine the optimal strategy. We reviewed 1239 patients with advanced MHBO who underwent endoscopic stent placement as the primary treatment in 4 tertiary centers. Among them, 633 eligible patients were identified and classified into 4 groups: bilateral metal stent placement (BMS), unilateral metal stent placement (UMS), bilateral plastic stent placement (BPS), and unilateral plastic stent placement (UPS). The outcomes were compared before and after propensity score matching (PSM). After PSM, 87, 97, 91, and 81 patients in the BMS, UMS, BPS, and UPS groups, respectively, were matched. The clinical success rates were 98.9%, 83.5%, 71.4%, and 65.4% in the BMS, UMS, BPS, and UPS groups (P < .001), respectively. The postprocedural cholangitis rates were 8.0%, 17.5%, 26.4%, and 29.6% (P = .002), respectively. The median symptom-free stent patency was 9.6, 6.8, 4.6, and 4.2 months (P < .001), respectively. The mean number of interventions required was 1.2 ± 0.5, 1.7 ± 0.8, 2.0 ± 1.4, and 1.9 ± 1.3 (P < .001), respectively. The median (95% confidence interval) overall survival (OS) was 7.1 (6.0-8.2), 4.4 (3.8-4.9), 4.1 (2.9-5.2), and 2.7 (1.8-3.7) months (P = .001), respectively. Compared with plastic stent placement, metal stent placement achieved higher success in all outcome parameters (P ≤ .001). Bilateral stent placement was superior to unilateral stent placement in terms of clinical success (P = .024), stent patency (P = .018), and OS (P = .040). If technically possible, dual metal stent placement is a preferred palliation for inoperable MHBO, and unilateral metal stent placement is the second option. [Display omitted]